Morbus Wilson und Hämochromatose

Susanne Domschke; Isabelle Mohr; Uta Merle

doi:10.1055/a-1057-1163

Gastroenterologie up2date, Table of Contents

Gastroenterologie up2date 2020; 16(02): 157-172
DOI: 10.1055/a-1057-1163

Leber/Galle/Pankreas

Georg Thieme Verlag KG Stuttgart · New York

Morbus Wilson und Hämochromatose

Susanne Domschke

,

Isabelle Mohr

,

Uta Merle

Abstract

All articles of this category

Der Morbus Wilson und die HFE-assoziierte Hämochromatose sind autosomal-rezessiv vererbte Stoffwechselkrankheiten der Leber. Die Kenntnis ihrer Symptome und der diagnostischen Schritte zur Abklärung ist wichtig – denn für beide Erkrankungen gilt: Die rechtzeitige Diagnosestellung und der frühe Therapiebeginn beeinflussen entscheidend die Prognose der Patienten. Dieser Beitrag gibt einen praxisnahen Überblick über beide Stoffwechselkrankheiten.

Schlüsselwörter

Morbus Wilson - Kupferspeichererkrankung - Kayser-Fleischer-Kornealring - Hämochromatose - Eisenstoffwechselstörung

Full Text

References

Literatur
1 European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilsonʼs disease. J Hepatol 2012; 56: 671-685
2 Eisenbach C, Sieg O, Stremmel W. et al. Diagnostic criteria for acute liver failure due to Wilson disease. World J Gastroenterol 2007; 13: 1711-1714
3 Pfeiffenberger J, Mogler C, Gotthardt DN. et al. Hepatobiliary malignancies in Wilson disease. Liver Int 2015; 35: 1615-1622
4 Srinivas K, Sinha S, Taly AB. et al. Dominant psychiatric manifestations in Wilsonʼs disease: a diagnostic and therapeutic challenge!. J Neurol Sci 2008; 266: 104-108
5 Merle U, Schaefer M, Ferenci P. et al. Clinical presentation, diagnosis and long-term outcome of Wilsonʼs disease: a cohort study. Gut 2007; 56: 115-120
6 Steindl P, Ferenci P, Dienes HP. et al. Wilsonʼs disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997; 113: 212-218
7 Ganaraja B, Pavithran P, Ghosh S. Effect of estrogen on plasma ceruloplasmin level in rats exposed to acute stress. Indian J Med Sci 2004; 58: 150-154
8 Ferenci P, Steindl-Munda P, Vogel W. et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilsonʼs disease. Clin Gastroenterol Hepatol 2005; 3: 811-818
9 Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. Hum Genet 2006; 120: 151-159
10 El Balkhi S, Poupon J, Trocello JM. et al. Determination of ultrafiltrable and exchangeable copper in plasma: stability and reference values in healthy subjects. Anal Bioanal Chem 2009; 394: 1477-1484
11 Poujois A, Woimant F. Wilsonʼs disease: A 2017 update. Clin Res Hepatol Gastroenterol 2018; 42: 512-520
12 European Association for Study of Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010; 53: 3-22
13 Kowdley KV, Brown KE, Ahn J. et al. ACG Clinical Guideline: Hereditary Hemochromatosis. Am J Gastroenterol 2019; 114: 1202-1218
14 Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet 2016; 388: 706-716
15 Asberg A, Hveem K, Halvorsen TB. et al. Prevalence of liver fibrosis and cirrhosis in screening-detected C282Y homozygous subjects. Scand J Gastroenterol 2007; 42: 782-783
16 Nicolas G, Viatte L, Bennoun M. et al. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 2002; 29: 327-335
17 Adams PC, Barton JC. Haemochromatosis. Lancet 2007; 370: 1855-1860
18 Guyader D, Jacquelinet C, Moirand R. et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998; 115: 929-936
19 Morrison ED, Brandhagen DJ, Phatak PD. et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138: 627-633
20 Adhoute X, Foucher J, Laharie D. et al. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. Gastroenterol Clin Biol 2008; 32: 180-187
21 Ong SY, Gurrin LC, Dolling L. et al. Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial. Lancet Haematol 2017; 4: e607-e614
22 Niederau C, Fischer R, Pürschel A. et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107-1119
23 Bardou-Jacquet E, Lainé F, Guggenbuhl P. et al. Worse Outcomes of Patients With HFE Hemochromatosis With Persistent Increases in Transferrin Saturation During Maintenance Therapy. Clin Gastroenterol Hepatol 2017; 15: 1620-1627